| Date | Title | | | 05/15/12 | Celldex Therapeutics Added to Nasdaq Biotechnology Index| NEEDHAM, Mass.--(BUSINESS WIRE)--May. 15, 2012-- Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that the Company will be added to the NASDAQ Biotechnology Index® (NBI), effective prior to market open on Monday, May 21, 2012. The NBI includes biotechnology or pharmaceutical companies listed exclusively on the NASDAQ Global Select Market or on the NASDAQ Global Market that meet predetermined eligibility requirements, including a minimum market capitalization of $200 million and an avera... |
|  | | 05/03/12 | Celldex Reports First Quarter 2012 Financial Results| NEEDHAM, Mass.--(BUSINESS WIRE)--May. 3, 2012-- Celldex Therapeutics, Inc. (NASDAQ: CLDX) today reported financial results for the first quarter ended March 31, 2012. Celldex reported a net loss of $13.5 million, or $0.27 per share, for the first quarter of 2012 compared to a net loss of $10.1 million, or $0.31 per share, for the first quarter of 2011. At March 31, 2012, Celldex reported cash, cash equivalents and marketable securities of $92.1 million, which the Company believes will be suffici... |
| | | 05/01/12 | Celldex Announces Plans to Release Topline Results from the EMERGE Study in Advanced Breast Cancer| Webcast scheduled for May 23
NEEDHAM, Mass.--(BUSINESS WIRE)--May. 1, 2012-- Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that interim, topline results of the Phase 2b EMERGE study of CDX-011 in patients with advanced breast cancer will be presented in a webcast on May 23, 2012. Linda Vahdat, MD, Professor of Medicine, Chief of Solid Tumor Service and Director of the Breast Cancer Research Program at Weill Cornell Medical College and the lead investigator of the EMERGE study, will... |
| | | 03/14/12 | Celldex Announces Exercise of Over-Allotment Option| NEEDHAM, Mass.--(BUSINESS WIRE)--Mar. 14, 2012-- Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that the underwriters of its previously announced public offering of common stock have exercised in full their overallotment option to purchase an additional 1,575,000 shares of common stock at the public offering price of $3.85 per share, less underwriting discounts and commissions. Proceeds from the exercise of the option will be approximately $5.7 million, after deducting underwriting di... |
| | | 03/07/12 | Celldex Reports Fourth Quarter and Fiscal 2011 Financial Results| - Management to Host Conference Call to Discuss Results and Provide 2012 Outlook Today, Wednesday, March 7, at 8:30 a.m. Eastern Time -
NEEDHAM, Mass.--(BUSINESS WIRE)--Mar. 7, 2012-- Celldex Therapeutics, Inc. (NASDAQ: CLDX) today reported financial results for the fourth quarter and the year ended December 31, 2011. Celldex reported a net loss of $12.7 million, or ($0.29) per basic and diluted share, for the fourth quarter of 2011 compared to net income of $22.7 million, or $0.71 basic earni... |
| | | 02/29/12 | Celldex Therapeutics to Host Corporate 2011 Year-End and 2012 Objectives Update Call| - Call scheduled for March 7, 2012 at 8:30 a.m. -
NEEDHAM, Mass.--(BUSINESS WIRE)--Feb. 29, 2012-- Celldex Therapeutics, Inc. (NASDAQ: CLDX) will host a conference call before U.S. financial markets open at 8:30 a.m. Eastern Time on Wednesday, March 7, 2012, to provide a year-end summary for 2011 and an update on anticipated research and development and business objectives for 2012.
The conference call will be webcast live over the Internet and can be accessed by logging on to the Events Cal... |
| | | 02/24/12 | Celldex Therapeutics to Present at the Citi 2012 Global Health Care Conference| NEEDHAM, Mass.--(BUSINESS WIRE)--Feb. 24, 2012-- Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that Anthony S. Marucci, President and Chief Executive Officer of Celldex Therapeutics, Inc., will present at the Citi 2012 Global Health Care Conference in New York City on Tuesday, February 28, 2012 at 9:30 a.m. Eastern Time.
A live webcast of the presentation will be available on the “Events Calendar” page of the “News & Events” section of Celldex’s website at http://www.celldexthe... |
| | | 02/24/12 | Celldex Prices Public Offering of Common Stock| NEEDHAM, Mass.--(BUSINESS WIRE)--Feb. 24, 2012-- Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 10,500,000 shares of its common stock, offered at a price to the public of $3.85 per share for an aggregate offering of $40,425,000 of common stock. The net proceeds to Celldex from this offering are expected to be approximately $37,744,500, after deducting underwriting discounts and commissions and other estimated offering expenses payable ... |
| | | 02/23/12 | Celldex Announces Public Offering of Common Stock| NEEDHAM, Mass.--(BUSINESS WIRE)--Feb. 23, 2012-- Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that it is offering shares of its common stock in an underwritten public offering. All of the shares in the offering will be sold by Celldex. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The shares will be issued pursuant to a prospectus supplement filed as ... |
| | | 02/09/12 | Celldex Therapeutics to Participate on Therapeutic Workshop Panel at the BIO CEO & Investor Conference| NEEDHAM, Mass.--(BUSINESS WIRE)--Feb. 9, 2012-- Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that Thomas Davis, M.D., Senior Vice President and Chief Medical Officer of Celldex Therapeutics, Inc., will participate with other industry executives in a therapeutic workshop panel discussion titled Drugs Need Friends Too – Companion Diagnostics and Drug Development. The panel will be moderated by Steve Brozak, President, WBB Securities LLC, at the 14th Annual BIO CEO & Investor Confe... |
| | | 01/18/12 | Celldex Therapeutics to Host Research and Development Day Highlighting Oncology Pipeline| NEEDHAM, Mass.--(BUSINESS WIRE)--Jan. 18, 2012-- Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that it will host a research and development day for the investment community on Monday, January 23, 2012 at 8:30 am Eastern Time. The event will provide updates on the Company’s robust pipeline in oncology and cancer immunotherapy, featuring presentations from leading researchers and investigators as well as Celldex management. For information on attending the event, please contact Sarah C... |
| | | 01/17/12 | Celldex Therapeutics Announces Initiation of Phase 1 Clinical Trial of CDX-301| NEEDHAM, Mass.--(BUSINESS WIRE)--Jan. 17, 2012--
Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that dosing
has initiated in a Phase 1 study of its hematopoietic growth factor,
CDX-301, in healthy subjects. The study is being conducted in
collaboration with Rockefeller University. CDX-301 is soluble,
recombinant human FMS-like tyrosine kinase 3 ligand (Flt3L) and previous
experience has shown that it increases the numbers and activity of b... |
| | | 01/04/12 | Celldex Initiates a Phase 2 Study of Rindopepimut in Patients with Recurrent Glioblastoma including Avastin® Naive and Refractory Populations| - Vaccine Targets Patients with EGFRvIII-positive Recurrent Glioblastoma -
NEEDHAM, Mass.--(BUSINESS WIRE)--Jan. 4, 2012-- Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that patient screening has initiated in a Phase 2 trial of rindopepimut in combination with Avastin® in patients with recurrent epidermal growth factor variant III (EGFRvIII)-positive glioblastoma, called the “ReACT Study.” This new study will run in parallel with Celldex’s Phase 3 trial (ACT IV) evaluating rindopep... |
| |
|
